Bayer and Dewpoint Therapeutics co-development deal for cardiovascular and gynecological diseases
Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement... Read More
Bayer received EU marketing authorization for the precision oncology treatment Vitrakvi (larotrectinib)
Bayer announced that the European Commission has granted marketing authorization in the European Union (EU) for the precision oncology treatment Vitrakvi (larotrectinib).... Read More
Top 10 Global Pharmaceutical Company in 2018
Posted on26 May 2019
Comments0
Bayer to launch Baycox Iron injection combination in Europe
Bayer launches Baycox Iron (36 mg/ml toltrazuril plus 182 mg/ml gleptoferron) suspension for injection for piglets across Europe following marketing authorization from... Read More
Insight on USFDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor
Posted on29 Nov 2018
Comments0
The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult... Read More
Insight on Bayer’s EU approval of new treatment regimen for Eylea
Bayer has received European Commission approval of a new treatment approach for Eylea to enable clinicians to combine proactive treatment with early... Read More
Case Study: LEO Pharma’s acquisition of Bayer’s dermatology unit
LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit. The portfolio to be acquired includes branded... Read More
Bayer’s strategic alliance with Broad Institute of MIT and Harvard
Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel... Read More
Bayer, VUMC strategic research collaboration to develop therapies against kidney diseases
Posted on13 Sep 2017
Comments0
Bayer and Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, US, have entered on a five-year strategic research alliance in the area of... Read More
$62bn bids by Bayer for GM seed giant Monsanto
German drug and chemicals group Bayer has offered to buy the American GM seed pioneer Monsanto for $62bn (£43bn) in a deal... Read More